A syringe for intraperitoneal injection of polypeptide powder

Abstract

The present invention discloses a syringe for intraperitoneal injection of polypeptide powder, which comprises a syringe barrel and an injection piston arranged in the syringe barrel in a matching manner. A separation assembly is arranged between the injection port of the syringe barrel and the injection piston. The separation assembly includes: an inner piston, a separation plate and a needle. The inner piston is slidably connected to the side of the syringe barrel close to the injection port of the syringe barrel along the extending direction of the syringe barrel. A solvent is filled between the inner piston and the injection piston. The separation plate is located inside the syringe barrel. The first end of the separation plate is fixedly connected to the injection port of the syringe barrel. A blade portion is provided at the second end of the separation plate, and the blade portion abuts against the inner piston. The separation plate divides the inner space of the syringe barrel between the inner piston and the injection port into two separated chambers, and different polypeptide powders are placed in the two separated chambers. The needle is fixed on the separation plate, the tip of the needle is flush with the blade portion, and the opening of the needle is flush with the end of the separation plate, so that two polypeptide powders can be instantaneously mixed with the solvent at the bleeding site to form a hemostatic gel.

Description

Technical Field

[0001] The present invention relates to the field of injection devices, and particularly to a syringe for intraperitoneal injection of polypeptide powder.

[0002] Background Art.

[0003] Intraperitoneal injection of polypeptide powder is a method of administering polypeptide drugs by intraperitoneal injection. The polypeptide powder usually needs to be dissolved in a suitable solvent first and then injected after forming a solution.

[0004] In current abdominal hemostasis solutions, we have two main options. First, the US XStat rapid hemostasis system, which uses micro-cotton and chitosan to make a material that can expand 10 times in a few seconds to quickly close the wound and stop bleeding. However, the pusher of this system only compresses and stops bleeding through physical expansion and cannot directly reach the bleeding site. The other is the hydrogel hemostasis solution that has developed rapidly in recent years. It makes up for the deficiency that the XStat system cannot directly reach the bleeding site and achieves the hemostasis effect through physical and physiological mechanisms. However, as a gel state, the hydrogel has lower stability than polypeptide powder and higher costs in transportation and storage.

[0005] Currently, most common powder injection forms only contain powder components and need to be mixed with a solvent during use. Although this traditional mode is okay when used alone, in emergency rescue scenarios, when hemostasis treatment needs to be carried out on a patient, two unique polypeptide powders are required. These two unique polypeptide powders independently exhibit excellent hemostasis and antibacterial effects. However, when they are accidentally mixed, the intermolecular interactions inside will trigger a series of chronic chemical reactions. These reactions may not only weaken the original therapeutic effects of each other but also shorten the overall shelf life of the product. Therefore, the two different polypeptide powders need to be stored separately and mixed with the solvent respectively to form a hemostatic gel and applied to the abdominal affected area of the patient during use. Every second in an emergency rescue situation is crucial, and patients need to be treated quickly and effectively. This not only increases the complexity of the operation but may also delay precious first aid time. Summary of the Invention

[0006] The purpose of the present invention is to overcome the problems in the prior art and provide a syringe for intraperitoneal injection of polypeptide powder, which can be applicable to the emergency rescue environment and can instantaneously mix two polypeptide powders with a solvent at the bleeding site to form a hemostatic gel.

[0007] The present invention provides a syringe for intraperitoneal injection of polypeptide powder, comprising a syringe barrel and an injection piston disposed in the syringe barrel in a mating manner. A separation assembly is provided between the injection port of the syringe barrel and the injection piston. The separation assembly separates the solvent and two different polypeptide powders inside the syringe barrel from each other. The separation assembly includes: an inner piston, a separation plate and a needle. The inner piston is slidably connected to the side of the syringe barrel close to the injection port of the syringe barrel along the extending direction of the syringe barrel. Solvent is filled between the inner piston and the injection piston. The separation plate is located inside the syringe barrel. The first end of the separation plate is fixedly connected to the injection port of the syringe barrel. A blade portion is provided at the second end of the separation plate. The blade portion abuts against the inner piston. The separation plate divides the inner space of the syringe barrel between the inner piston and the injection port into two separated chambers. Different polypeptide powders are placed in the two separated chambers. The needle is fixed on the separation plate. The tip of the needle is flush with the blade portion, and the opening of the needle is flush with the end of the separation plate. As the injection piston moves towards the injection port, the blade portion can cut through and penetrate the inner piston, and the solvent enters through the tip of the needle and flows out from the opening of the needle to be mixed with the polypeptide powder outside the injection port.

[0008] Optionally, the inner piston is made of an elastic material.

[0009] Optionally, the inner barrel cavity of the syringe barrel includes a first cavity section and a second cavity section connected along its extending direction. The first cavity section communicates between the injection port and the second cavity section. The inner diameter of the first cavity section is smaller than that of the second cavity section, and the first cavity section and the second cavity section are smoothly transitioned.

[0010] Optionally, the inner diameter of the first cavity section gradually decreases from the end close to the second cavity section towards the end far from it.

[0011] Optionally, the inclination angle of the first cavity section is 45 degrees, and a superhydrophobic nano-coating is covered on the cavity walls of the first cavity section and the second cavity section.

[0012] Optionally, the superhydrophobic nano-coating adopts an antibacterial superhydrophobic nano-coating with metal nanoparticles.

[0013] Optionally, a first Luer connector is provided at the injection port of the syringe barrel, and a corresponding second Luer connector is provided on the needle cap. The first Luer connector and the second Luer connector are detachably connected.

[0014] Optionally, it further includes: a plurality of extended drug delivery tubes with different lengths. One end of each extended drug delivery tube is provided with a third Luer connector for mating with the first Luer connector. The third Luer connector and the first Luer connector are detachably connected.

[0015] Optionally, the separation plate is made of transparent glass.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows: In the storage state before use of a syringe for intraperitoneal injection of polypeptide powder provided by the present invention, the syringe barrel between the internal piston and the injection piston is filled with a solvent such as physiological saline, and two different polypeptide powders are filled in the isolation chambers on both sides of the isolation plate. At this time, the needle cap closes the injection port, and one end of the isolation plate is located at the injection port and the other end abuts against the internal piston, thus ensuring the closed state of the isolation chambers on both sides of the isolation plate and avoiding the premature leakage and mixing of the two polypeptide powders. When in use, remove the needle cap, align it with the wound, insert the injection port into the wound, and push the injection piston. As a result, the injection piston, the physiological saline, and the internal piston move together toward the side of the injection port. During this process, the cutting edge of the isolation plate gradually cuts and enters the internal piston. As the internal piston moves, the isolation plate and the tip of the needle pass through the internal piston together, so that the tip of the needle enters the space between the internal piston and the injection piston. The physiological saline enters the needle and flows out of the opening of the needle to the outside of the injection port. At the same time, the internal piston cut through by the isolation plate and the tip still maintains the closure of the end of the isolation chamber away from the injection port, so as to gradually push the two polypeptide powders in the isolation chamber out of the injection port and mix with the physiological saline simultaneously pushed out from the needle, so as to be mixed at the wound to form a hemostatic gel, achieving the effect of hemostasis, thus adapting to the wartime environment, and separating dry and wet, reducing the humidity of the powder and lowering the friction between the powders. Description of the Drawings

[0017] Figure 1 The first overall structural sectional view of a syringe for intraperitoneal injection of polypeptide powder provided by an embodiment of the present invention;

[0018] Figure 2 The second overall structural sectional view of a syringe for intraperitoneal injection of polypeptide powder provided by an embodiment of the present invention.

[0019] Description of the Reference Numerals:

[0020] 1. Syringe barrel; 11. First chamber section; 12. Second chamber section; 2. Injection piston; 3. Needle cap; 4. Internal piston; 5. Isolation plate; 6. Needle; 7. Push rod. Detailed Embodiments

[0021] The following describes the detailed embodiments of the present invention in detail, but it should be understood that the protection scope of the present invention is not limited by the detailed embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.

[0022] In an emergency rescue scenario, when hemostasis treatment is required for a patient, two unique polypeptide powders are needed. These two unique polypeptide powders independently exhibit excellent hemostatic and antibacterial efficacy. However, when they are accidentally mixed, the intermolecular interactions will trigger a series of chronic chemical reactions. These reactions may not only weaken their original therapeutic effects but also shorten the overall shelf life of the products. Therefore, the two different polypeptide powders need to be stored separately and mixed with a solvent respectively when in use to form a hemostatic gel and apply it to the abdominal affected area of the patient. Every second in an emergency rescue situation is crucial, and the patient needs to be treated quickly and effectively. This not only increases the complexity of the operation but also may delay precious first aid time.

[0023] Therefore, an embodiment of the present invention provides a syringe for intraperitoneal injection of polypeptide powder, which can instantaneously mix two polypeptide powders with a solvent at the bleeding site to form a hemostatic gel.

[0024] At least one embodiment of the present invention provides a syringe for intraperitoneal injection of polypeptide powder, including a syringe barrel and an injection piston disposed in the syringe barrel in cooperation. An isolation component is provided between the injection port of the syringe barrel and the injection piston. The isolation component isolates the solvent and two different polypeptide powders inside the syringe barrel from each other. The isolation component includes: an inner piston, an isolation plate, and a needle. The inner piston is slidably connected to the side of the syringe barrel close to the injection port of the syringe barrel along the extending direction of the syringe barrel. Solvent is filled between the inner piston and the injection piston. The isolation plate is located inside the syringe barrel. The first end of the isolation plate is fixedly connected to the injection port of the syringe barrel. The second end of the isolation plate is provided with a blade portion, and the blade portion abuts against the inner piston. The isolation plate divides the inner space of the syringe barrel between the inner piston and the injection port into two isolation chambers, and different polypeptide powders are placed in the two isolation chambers. The needle is fixed on the isolation plate. The tip of the needle is flush with the blade portion, and the opening of the needle is flush with the end of the isolation plate. As the injection piston moves towards the injection port, the blade portion can cut through and pass through the inner piston, and the solvent enters through the tip of the needle and flows out from the opening of the needle to mix with the polypeptide powder outside the injection port.

[0025] In the syringe for intraperitoneal injection of polypeptide powder provided by the above embodiment of the present invention, the two polypeptide powders can be stored separately through the isolation plate, and the solvent is stored in the space between the injection piston and the inner piston. When in use, the inner piston is cut by the blade portion, so that the solvent flows out from the opening of the needle and injects out of the injection port to mix with the polypeptide powder outside the injection port to form a hemostatic gel at the bleeding site of the patient.

[0026] The present invention will be described below through several specific embodiments. To keep the description below of the embodiments of the present invention clear and concise, the detailed description of known functions and known components may be omitted. When any component of the embodiments of the present invention appears in more than one drawing, the component may be represented by the same reference numeral in each drawing.

[0027] Reference Figure 1 , Figure 1 Figure 1 is a first overall structural sectional view of a syringe for intraperitoneal injection of polypeptide powder provided by an embodiment of the present invention. As Figure 1 shown, an embodiment of the present invention provides a syringe for intraperitoneal injection of polypeptide powder, including a syringe barrel 1 and an injection piston 2 disposed in cooperation with the syringe barrel 1. An isolation assembly is disposed between the injection port of the syringe barrel 1 and the injection piston 2. The isolation assembly isolates the solvent and two different polypeptide powders inside the syringe barrel 1 from each other. The isolation assembly includes: an inner piston 4, an isolation plate 5, and a needle 6. The syringe barrel 1 and the injection piston 2 disposed in cooperation with the syringe barrel 1. An isolation assembly is disposed between the injection port of the syringe barrel 1 and the injection piston 2. The inner piston 4 is slidably connected to the side of the syringe barrel 1 close to the injection port of the syringe barrel 1 along the extending direction of the syringe barrel 1. A solvent is filled between the inner piston 4 and the injection piston 2. The isolation plate 5 is located inside the syringe barrel 1. The first end of the isolation plate 5 is fixedly connected to the injection port of the syringe barrel 1. A cutting edge is provided at the second end of the isolation plate 5. The cutting edge abuts against the inner piston 4. The isolation plate 5 divides the inner space of the syringe barrel 1 between the inner piston 4 and the injection port into two isolation chambers. Different polypeptide powders are placed in the two isolation chambers. The needle 6 is fixed on the isolation plate 5. The tip of the needle 6 is flush with the cutting edge. The opening of the needle 6 is flush with the end of the isolation plate 5. As the injection piston 2 moves towards the injection port, the cutting edge can cut through and penetrate the inner piston 4. The solvent enters through the tip of the needle 6 and flows out from the opening of the needle 6 to be mixed with the polypeptide powder outside the injection port. It should be understood that a needle cap 3 is provided at the injection port, and the injection piston 2 is fixedly connected to a push rod 7.

[0028] Specifically, please refer to Figure 1 , in the storage state before use, physiological saline is filled in the syringe barrel 1 between the inner piston 4 and the injection piston 2. Two different polypeptide powders are filled in the isolation chambers on both sides of the isolation plate 5. At this time, the needle cap 3 closes the injection port, and one end of the isolation plate 5 is located at the injection port, and the other end abuts against the inner piston 4, thereby ensuring the closed state of the isolation chambers on both sides of the isolation plate 5 and avoiding the premature leakage and mixing of the polypeptide powder.

[0029] During use, remove the needle cap 3, align the injection port with the wound, and insert the injection port into the wound. Push the push rod 7 to drive the injection piston 2, so that the injection piston 2, the physiological saline, and the inner piston 4 move together towards the injection port side.

[0030] During this process, the cutting edge of the isolation plate 5 gradually cuts through and enters the inner piston 4.

[0031] With the movement of the inner piston 4, the isolation plate 5 and the tip of the needle 6 pass through the inner piston 4 together, so that the needle 6 enters the space between the inner piston 4 and the injection piston 2, enabling the normal saline to enter the needle 6 and flow out of the opening of the needle to the outside of the injection port. At the same time, the inner piston 4 cut through by the isolation plate 5 and the needle 6 still keeps the end of the isolation chamber away from the injection port closed, thereby gradually pushing the two powder agents in the isolation chamber out of the injection port and mixing them with the normal saline simultaneously pushed out from the needle 6, so as to be mixed at the wound site to form a hemostatic gel, achieving the technical effect of rapid hemostasis.

[0032] The syringe for intraperitoneal injection of polypeptide powder agents provided by the present invention is not only convenient for rapid deployment, but also ensures that in an emergency, medical staff can quickly and accurately mix the hemostatic powder and the antibacterial liquid in the optimal ratio, achieving an immediate and efficient treatment effect. At the same time, it is convenient to carry so that it can be easily carried and used in complex environments such as emergency rescue situations, truly saving every minute and second to save lives.

[0033] The syringe provided by the present invention can not only penetrate deep into the abdominal cavity and directly act on the bleeding site to achieve rapid physical and physiological hemostasis, but also maintain the high stability of the polypeptide powder agent, reducing the costs of transportation and storage. In this way, we can solve the problems in the current hemostasis solutions at one stroke and provide a safer and more effective hemostasis solution for patients.

[0034] In this embodiment, the isolation plate 5 is made of hard transparent glass, and the morphology of the polypeptide powder agent can be observed in cooperation with the transparent syringe barrel 1. The blade part is set as a knife-like sharp blade flush with the tip of the needle 6, which is used to cut the inner piston simultaneously with the needle 6 to facilitate the movement of the inner piston 4.

[0035] In another embodiment, the isolation plate 5 can also be made of a metal material to avoid the fragmentation and failure of the isolation plate 5 made of glass material due to collision and vibration in the medical environment of emergency rescue situations. Moreover, even if the isolation plate 5 made of metal material has a certain deformation, it can still cut through and pass through the inner piston 4. In other embodiments, the isolation plate 5 can also be made of other common chemically inert rigid materials, such as hard resin, hard plastic or modified ceramic materials.

[0036] Specifically, the inner piston 4 is made of an elastic material. Due to the elasticity of the inner piston 4, during the process that the isolation plate 5 gradually enters and passes through the inner piston 4 with its blade part, due to the extrusion of the inner wall of the syringe barrel 1, it can keep close contact between the inner piston 4 and the isolation plate 5, preventing the normal saline from entering the isolation chamber from the cutting part between the isolation plate 5 and the inner piston 4, thus preventing the premature mixing of the normal saline and the powder agent in the isolation chamber and also avoiding the liquid leakage phenomenon at the cutting part between the inner piston 4 and the isolation plate 5.

[0037] Reference Figure 2 ,Figure 2 This is the second overall structural sectional view of a syringe for intraperitoneal injection of polypeptide powder provided by an embodiment of the present invention. As Figure 2 shown, the inner barrel cavity of the syringe barrel 1 includes a first cavity section 11 and a second cavity section 12 connected along its extending direction. The first cavity section 11 communicates between the injection port and the second cavity section 12. The inner diameter of the first cavity section 11 is smaller than that of the second cavity section 12, and the first cavity section 11 and the second cavity section 12 are smoothly transitioned, which can increase the smoothness of the polypeptide powder being pushed out of the injection port.

[0038] Specifically, the inner diameter of the first cavity section 11 gradually decreases from the end close to the second cavity section 12 to the end far away from it, so that the polypeptide powder can be smoothly pushed out along with the inclined plane.

[0039] Furthermore, the inclination angle of the first cavity section 11 is 45 degrees. The inner walls of the first cavity section 11 and the second cavity section 12 are covered with a superhydrophobic nano - coating, which can increase the smoothness of the polypeptide powder being pushed out of the injection port, and further improve the operation convenience and reliability. The application of the superhydrophobic nano - coating in the polypeptide powder pushing can be mainly reflected in the following aspects:

[0040] I. Reducing frictional resistance

[0041] The superhydrophobic nano - coating has excellent drag - reducing performance. During the pushing process of the polypeptide powder, the coating can form a smooth and non - adhesive barrier on the inner surface of the pipeline or equipment, significantly reducing the frictional resistance between the polypeptide powder and the pipeline wall. This not only helps to improve the efficiency of polypeptide powder pushing, but also reduces energy consumption and equipment wear.

[0042] II. Preventing polypeptide powder caking and blocking

[0043] Polypeptide powder is prone to caking or blocking the pipeline due to reasons such as moisture absorption and static electricity during the conveying process. The superhydrophobic nano - coating can endow the surface with excellent hydrophobic properties, effectively preventing moisture or other liquids from penetrating into the polypeptide powder, thus reducing the risk of polypeptide powder caking. At the same time, the smooth surface of the coating can also reduce the adhesion and deposition of the polypeptide powder in the pipeline, further preventing the occurrence of blocking phenomena.

[0044] III. Improving the corrosion resistance and durability of equipment

[0045] Some corrosive components may be contained in the polypeptide powder, which can damage the material of the conveying equipment. The superhydrophobic nano - coating has excellent corrosion resistance, and can form a protective layer on the equipment surface, effectively isolating the contact between corrosive substances and the equipment material, thereby extending the service life of the equipment.

[0046] IV. Promoting the uniformity and stability of polypeptide powder pushing

[0047] The smooth surface and drag reduction performance of the superhydrophobic nanocoating contribute to the uniform flow of the polypeptide powder in the pipeline, reducing fluctuations and impacts caused by uneven flow rates or pressure fluctuations. This helps to improve the stability and consistency of the polypeptide powder delivery, ensuring that the polypeptide powder can be accurately delivered to the target position according to the predetermined amount and speed.

[0048] Furthermore, the superhydrophobic nanocoating adopts an antibacterial superhydrophobic nanocoating with metal nanoparticles. Since this embodiment belongs to a medical device and is applied to the first aid scenario in an emergency rescue situation, the sterility of the device needs to be considered. Therefore, the superhydrophobic nanocoating covered on the inner walls of the first cavity section 11 and the second cavity section 12 is considered to adopt an antibacterial superhydrophobic nanocoating with metal nanoparticles. The metal nanoparticles in the coating react with bacteria, subsequently causing various types of cell damage, such as lipid peroxidation, DNA damage, and protein oxidation, etc., thus leading to cell death to enhance the sterility of the device.

[0049] In this embodiment, the coating spraying raw material is selected as NanoxTM S2613P nano Al2O3-13% TiO2 powder, with a particle size of 50-500 nm, and the composition (by mass fraction) is: w(Al2O3)∶w(TiO2)= 87∶13, CeO2 6%-8%, ZrO2 8%-10%. The nano Al2O3-13% TiO2 powder is prepared by uniformly mixing Al2O3, TiO2, ZrO2, and CeO2 particles and then undergoing processes such as spray granulation, plasma flame treatment, and heat treatment. Other antibacterial superhydrophobic nanocoatings with similar compositions can also be used.

[0050] Furthermore, a first Luer connector is provided at the injection port of the syringe 1, and a corresponding second Luer connector is provided on the needle cap 3. The first Luer connector and the second Luer connector are detachably connected. The needle cap 3 and the needle 6 are docked together through the first Luer connector, with a threaded structure and precise combination to prevent transportation contamination and leakage.

[0051] Furthermore, it also includes multiple extended drug delivery tubes with different lengths. One end of each extended drug delivery tube is provided with a third Luer connector that mates with the first Luer connector. The third Luer connector and the first Luer connector are detachably connected, which is convenient for assembly. In this way, the extended drug delivery tube can be selected according to the position of the abdominal injury to ensure that the drug is directly delivered to the injury site, and the extended injection tube is not likely to fall off during injection.

[0052] Although the embodiments of the present invention have been shown and described, for those of ordinary skill in the art, it is understood that various changes, modifications, substitutions, and variations can be made to these embodiments without departing from the principles and spirit of the present invention. The scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A syringe for intraperitoneal injection of polypeptide powder, comprising a syringe barrel (1) and an injection piston (2) cooperatively arranged in the syringe barrel (1), characterized in that, A separation component is provided between the injection port of the syringe barrel (1) and the injection piston (2). The separation component separates the solvent inside the syringe barrel (1) and two different polypeptide powders from each other. The separation component includes: An inner piston (4) is slidably connected to the side of the syringe barrel (1) close to the injection port of the syringe barrel (1) along the extending direction of the syringe barrel (1). Solvent is filled between the inner piston (4) and the injection piston (2). A separation plate (5) is located inside the syringe barrel (1). The first end of the separation plate (5) is fixedly connected to the injection port of the syringe barrel (1). A cutting edge is provided at the second end of the separation plate (5). The cutting edge abuts against the inner piston (4). The separation plate (5) divides the inner space of the syringe barrel (1) between the inner piston (4) and the injection port into two separated chambers, and different polypeptide powders are placed in the two separated chambers. A needle (6) is fixed on the separation plate (5). The tip of the needle (6) is flush with the cutting edge, and the opening of the needle (6) is flush with the end of the separation plate (5). As the injection piston (2) moves towards the injection port, the cutting edge can cut through and penetrate the inner piston (4), and the solvent enters through the tip of the needle (6) and flows out from the opening of the needle (6) to be mixed with the polypeptide powder outside the injection port. The inner barrel cavity of the syringe barrel (1) includes a first cavity section (11) and a second cavity section (12) connected along its extending direction. The first cavity section (11) communicates between the injection port and the second cavity section (12). The inner diameter of the first cavity section (11) is smaller than that of the second cavity section (12), and the first cavity section (11) and the second cavity section (12) are smoothly transitioned.

2. The syringe for intraperitoneal injection of polypeptide powder according to claim 1, characterized in that, The inner piston (4) is made of an elastic material.

3. The syringe for intraperitoneal injection of polypeptide powder as claimed in claim 1, wherein, The inner diameter of the first cavity section (11) gradually decreases from the end close to the second cavity section (12) to the end away from it.

4. The syringe for intraperitoneal injection of polypeptide powder according to claim 3, characterized in that, The inclination angle of the first cavity section (11) is 45 degrees. The inner walls of the first cavity section (11) and the second cavity section (12) are covered with a superhydrophobic nano-coating.

5. The syringe for intraperitoneal injection of polypeptide powder according to claim 4, characterized in that, The superhydrophobic nano-coating adopts an antibacterial superhydrophobic nano-coating with metal nanoparticles.

6. The syringe for intraperitoneal injection of polypeptide powder according to claim 1, characterized in that A first Luer connector is provided at the injection port of the syringe barrel (1). A needle cap (3) is provided at the injection port. A corresponding second Luer connector is provided on the needle cap (3). The first Luer connector and the second Luer connector are detachably connected.

7. The syringe for intraperitoneal injection of polypeptide powder according to claim 6, wherein, It further includes: Multiple extended administration tubes, each extended administration tube having a different length. One end of the extended administration tube is provided with a third Luer connector adapted to the first Luer connector. The third Luer connector and the first Luer connector are detachably connected.

8. The syringe for intraperitoneal injection of polypeptide powder according to claim 1, wherein Characterized in that The separation plate (5) is made of transparent glass.

Images